The pharmaceutical marketplace had been changing due to business consolidation that was leading although Takeda rated approximately 15th in international sales. Yasuchika Hasegawa, the president of Takeda, was concerned about the future of the company. Its business had enlarged to foreign markets to counter the decreasing Japanese pharmaceutical market. But the efforts to become a worldwide business of Takeda had been criticized as slow and not sufficiently aggressive.
Worse, Takeda's R&D pipeline was shrinking, and patents on several of its leading products were about to expire-which would inevitably lead to a decline in profits as generics entered the market. This case investigates the plan to transform Takeda into a global pharmaceutical company in a rapidly changing marketplace of Hasegawa. It covers Takeda's history, business trends, and the acquisition strategies of Hasegawa.
Takeda Pharmaceutical Company Becoming a Global Company A case study solution
PUBLICATION DATE: January 17, 2012 PRODUCT #: OB83A-HCB-ENG
This is just an excerpt. This case is about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
Cause-Related Marketing: More Buck than Bang
Alessi: Evolution of an Italian Design Factory (A)
Peripheral Products Co.: The Gray Market for Disk Drives
Waters Chromatography Division: U.S. Field Sales (A)
Benetton Group S.p.A., 2000
Environmental Compliance at Suncor Energy’s Firebag Facility
Strategic Plan
David’s Bridal: A Proposal for a New Generation
Hindustan Lever at the Base of the Pyramid: Growth for the 21st Century
Implementing Sales Force Automation at Quantum Technology
